prodrug, as described herein, or the cellulose based polymer or pharmaceutically acceptable salt thereof or prodrug or combination of any of the foregoing in therapeutically or prophylatically effective amounts, respectively. 

[0079] The present invention is also directed to a pharma› ceutical composition comprising a therapeutically effective amount of an anionic cellulose-based polymer or a pharma› ceutically acceptable salt thereof or prodrug thereof or an anionic acrylic-based polymer or pharmaceutically accept› able salt thereof or a prodrug thereof or a combination thereof in association with a pharmaceutically acceptable carrier, vehicle, or diluent. 

[0080] The present invention is also directed to polymers having repeating units of Formula I or II, as described herein or pharmaceutically acceptable salts of polymers of Formula I or II or prodrugs of polymers of Formula I or II for the utility described herein. 

[0081] The present invention also provides pharmaceuti› cal compositions comprising a therapeutically effective amount of the anionic cellulose-based polymer or the anionic acrylic-based polymer described herein, a prodrug of either said anionic cellulose-based polymer or anionic acrylic-based polymer, or a combination thereof or a phar› maceutically acceptable salt of said anionic cellulose based polymer or acrylic-based polymer or prodrug; and a phar› maceutically acceptable carrier, vehicle or diluent. The pharmaceutical compositions can be delivered in a liquid or solid dosage form. Alternatively, the pharmaceutical com› positions can be incorporated into barrier devices such as condoms, diaphragms, or cervical caps. The pharmaceutical compositions described herein are useful for the treatment of a virus, bacterial, or fungal infection in a host. 

[0082] The present invention also provides methods for the treatment or prevention of a virus, bacterial, or fungal infection in a host, which comprises administering to the host a therapeutically effective amount of an anionic cellu› lose-based polymer, a prodrug thereof, or a pharmaceuti› cally acceptable salt of said anionic cellulose-based polymer or prodrug in combination with one or more anti-infective agents. More particularly, the one or more anti-infective agents can be an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, or a combination thereof. Further, the anionic cellulose-based polymer and the one or more anti› infective agents can be administered simultaneously or sequentially. 

[0083] In another embodiment, said one or more anti› infective agents in such methods include antiviral protease enzyme inhibitors (PI), virus DNA or RNA or reverse transcriptase (RT) polymerase inhibitors, virus/cell fusion inhibitors, virus integrase enzyme inhibitors, virus/cell bind› ing inhibitors, and/or virus or cell helicase enzyme inhibi› tors, bacterial cell wall biosynthesis inhibitors, virus or bacterial attachment inhibitors, HIV-1 RT inhibitors (such as Tenofovir, epivir, zidovudine, or stavudine, and the like), HIV-1 protease inhibitors ( such as saquinavir, ritonavir, nelfmavir, indinavir, amprenavir, lopinavir, atazanavir, tipranavir, fosamprenavir, and the like), HIV-1 fusion inhibi› tors (such as Fuzeon (T20), or PRO-542, SCH-C, and the like), polybiguanides (PBGs ), herpes virus DNA polymerase inhibitors (such as acyclovir, ganciclovir, cidofovir, and the like), herpes virus protease inhibitors, herpes virus fusion inhibitors, herpes virus binding inhibitors, and ribonucle› otide reductase inhibitors. 

[0084] The present invention also provides methods for the treatment or prevention of a virus, bacterial, or fungal infection in a host, which comprises administering to the host a therapeutically effective amount of an anionic acrylic based polymer, a prodrug thereof, or a pharmaceutically acceptable salt of said anionic acrylic based polymer or prodrug in combination with one or more anti-infective agents. More particularly, the one or more anti-infective agents can be an anti-viral agent, an anti-bacterial agent, an anti-fingal agent, or combination thereof. More particularly, the anionic acrylic based polymer and the one or more anti-infective agents can be administered simultaneously or sequentially. 

[0085] In another embodiment, said one or more anti› infective agents of such methods include antiviral protease enzyme inhibitors (PI), virus DNA or RNA or reverse transcriptase (RT) polymerase inhibitors, virus/cell fusion inhibitors, virus integrase enzyme inhibitors, virus/cell bind› ing inhibitors, and/or virus or cell helicase enzyme inhibi› tors, bacterial cell wall biosynthesis inhibitors, virus or bacterial attachment inhibitors, HIV-1 RT inhibitors (such as Tenofovir, epivir, zidovudine, or stavudine, and the like), HIV-1 protease inhibitors ( such as saquinavir, ritonavir, nelfmavir, indinavir, amprenavir, lopinavir, atazanavir, tipranavir, fosamprenavir, and the like), HIV-1 fusion inhibi› tors (such as Fuzeon (T20), or PRO-542, SCH-C, and the like), polybiguanides (PBGs ), herpes virus DNA polymerase inhibitors (such as acyclovir, ganciclovir, cidofovir, and the like), herpes virus protease inhibitors, herpes virus fusion inhibitors, herpes virus binding inhibitors, and ribonucle› otide reductase inhibitors. 

[0086] The present invention also provides pharmaceuti› cal combination compositions comprising a therapeutically effective amount of a composition which comprises a thera› peutically effective amount of an anionic cellulose-based polymer, a prodrug of said anionic cellulose based polymer, or a pharmaceutically acceptable salt of said anionic cellu› lose-based polymer or prodrug; one or more anti-infective agents; and a pharmaceutically acceptable carrier, vehicle or diluent. 

[0087] In another embodiment, said one or more anti› infective agents in such pharmaceutical combination com› positions include antiviral protease enzyme inhibitors (PI), virus DNA or RNA or reverse transcriptase (RT) polymerase inhibitors, virus/cell fusion inhibitors, virus integrase enzyme inhibitors, virus/cell binding inhibitors, and/or virus or cell helicase enzyme inhibitors, bacterial cell wall bio› synthesis inhibitors, virus or bacterial attachment inhibitors, HIV-1 RT inhibitors (such as Tenofovir, epivir, zidovudine, or stavudine, and the like), HIV-1 protease inhibitors (such as saquinavir, ritonavir, nelfinavir, indinavir, amprenavir, lopinavir, atazanavir, tipranavir, fosamprenavir, and the like), HIV-1 fusion inhibitors (such as Fuzeon (T20), or PRO-542, SCH-C, and the like), polybiguanides (PBGs), herpes virus DNA polymerase inhibitors ( such as acyclovir, ganciclovir, cidofovir, and the like), herpes virus protease inhibitors, herpes virus fusion inhibitors, herpes virus bind› ing inhibitors, and ribonucleotide reductase inhibitors. 

[0088] The present invention also provides pharmaceuti› cal combination compositions comprising a therapeutically effective amount of a composition which comprises a thera› peutically effective amount of an anionic acrylic-based polymer, a prodrug of said anionic acrylic-based polymer, or 

